tamoxifen,Exemestane,Triptorelin
Astrazeneca,Pfizer,Azurity Pharmaceuticals
['bcsm', 'ovarian', 'core i', 'soft study']
 pam50 ror score is not predictive of ovarian function suppression benefit in premenopausal women in the soft study! important data to consider when making adjuvant therapy plans for our premenopausal patients #bcsm #asco23 
Breast Medical Oncologist @UNC_Lineberger Prior @JCO_ASCO editorial fellow. Views are my own.